CN103254110B - The full ketone of halogenated pyrrole substituted indole, its intermediate and preparation method thereof - Google Patents
The full ketone of halogenated pyrrole substituted indole, its intermediate and preparation method thereof Download PDFInfo
- Publication number
- CN103254110B CN103254110B CN201210036869.2A CN201210036869A CN103254110B CN 103254110 B CN103254110 B CN 103254110B CN 201210036869 A CN201210036869 A CN 201210036869A CN 103254110 B CN103254110 B CN 103254110B
- Authority
- CN
- China
- Prior art keywords
- compound
- preparation
- reaction
- alkali
- mol ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Indole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The invention discloses the preparation method of the dihydroindole ketone intermediate 3 that a kind of halogenated pyrrole replaces, it comprises the following steps: that temperature of reaction is 0 DEG C ~ 150 DEG C, in organic solvent, under the effect of alkali, compound 1 and compound 5 are reacted, obtain intermediate 3.The invention also discloses the preparation method of the full ketone I of a kind of halogenated pyrrole substituted indole, it comprises the following steps: 1. to obtain compound 3 by above-mentioned preparation method; 2. temperature of reaction is 25 DEG C ~ 120 DEG C, in organic solvent, and under the effect of alkali, the compound 3 and the compound 4 that step are 1. obtained react, and obtain Compound I.Preparation method of the present invention is easy and simple to handle, and aftertreatment is simple, and reaction scheme is shorter, and the products collection efficiency obtained is higher, is applicable to suitability for industrialized production.
Description
Technical field
The invention belongs to pharmaceutical chemistry synthesis field, be specifically related to dihydroindole ketone, its intermediate and preparation method thereof that a class halogenated pyrrole replaces.
Background technology
Malignant tumour is the major disease of harm people life and health, in recent years, along with the develop rapidly of oncobiology and related discipline, people recognize that the essence of cell carcinogenesis is the cell infinite multiplication that the imbalance of intracellular signal transduction pathway causes gradually, and the consequent is the great change of antitumor drug research and development theory.The focus of research and development transfers to the specificity a new generation antitumor drug for abnormal signal system target site in tumour cell from conventional cell cytotoxic drug.Be different from the feature such as conventional cell cytotoxic drug poor selectivity, strong, the easy generation resistance of toxic side effect, target spot specificity antineoplastic medicine is directed to the difference between normal cell and tumour cell, reaches highly selective, hypotoxic result for the treatment of.Based on the complicacy of tumor development, overwhelming majority tumour is not rely on a certain signal paths to maintain its growth and survival, also exist between signal path intersect and compensatory, molecular targeted antitumor drug treatment proposition challenge concept: the strategy of many targets tyrosine-kinase enzyme level (mul-tipletargetedtyrosinekinaseinhibition), this concept has obtained compellent clinical evidence.Two Mutiple Targets micromolecular compound Sutents (sunitinib) and BAY 43-9006 (sorafenib) are used for kidney by FDA confirmation sheet medicine recently respectively, wherein the Sutent simultaneously multiple Tyrosylprotein kinase such as target VEGF-2 and PDGFR, KIT and FLT3.
Sutent is that a class can first medicine in the newtype drug of the optionally multiple receptor tyrosine kinase of target.Suppressing receptor tyrosine kinase to be considered to can through blocking blood needed for tumor growth and nutritive substance supply and " die of hunger " tumour and tool kills activity of tumor cells simultaneously, and namely Sutent combines and stops to supply the anti-angiogenetic therapy of blood and these two kinds of mechanism of action antitumor of directtissima tumour cell to tumour cell.Sutent was U.S. FDA in 2006 as treatment advanced renal cell carcinoma and stomach to stroma cell knurl two indications as a Mutiple Targets specificity antineoplastic medicine, go through listing simultaneously, receive and note widely, clinical and fundamental research in recent years shows it to curative effects such as nonsmall-cell lung cancer, ovarian cancer, myelocytic leukemias, especially the combination therapy such as it and cytotoxicity series antineoplastic medicament, radiotherapy, monoclonal antibody drug, achieves positive effect and gets most of the attention.
The dihydroindole ketone new compound I that Chinese patent (CN101440086A) discloses a class halogenated pyrrole replacement demonstrates good antitumour activity.
Its preclinical study shows to have or better anti-tumor activity similar with Sutent, has a good application prospect.The typical synthetic route of formula I is as follows:
The following shortcoming and defect that this route exists: (1) compound 2 is thickness half oily matter, and suction filtration process is comparatively difficult, is not suitable for suitability for industrialized production; (2) reaction yield of formula I is low.
Summary of the invention
Technical problem to be solved by this invention be in order to overcome in prior art prepare the full ketone compounds of halogenated pyrrole substituted indole method in aftertreatment difficulty, productive rate is lower, be not suitable for suitability for industrialized production, and provide the full ketone of a kind of halogenated pyrrole substituted indole, its intermediate and preparation method thereof.Preparation method of the present invention is easy and simple to handle, and aftertreatment is simple, and reaction scheme is shorter, and the products collection efficiency obtained is higher, is applicable to suitability for industrialized production.
The invention provides the preparation method of the dihydroindole ketone intermediate 3 that a kind of halogenated pyrrole replaces, it comprises the following steps: that temperature of reaction is 0 DEG C ~ 150 DEG C, in organic solvent, under the effect of alkali, by the chloro-5-carboxaldehyde radicals of 2-methyl-4--3-minaline ethyl ester (compound 1) and N, N-diethyl ethylenediamine (compound 5) reacts, and obtains intermediate 3;
There is no particular limitation for described organic solvent, those skilled in the art can be applicable to organic solvent of the present invention according to what commonly use in selecting response this area of the present invention, preferred DMF, N-Methyl pyrrolidone, ether, alcohol or the aromatic hydrocarbon containing 6 ~ 8 carbon.Preferred Isosorbide-5-Nitrae-the dioxane of described ether, tetrahydrofuran (THF), glycol dimethyl ether or trimethyl carbinol dme.Described alcohol is preferably containing the alcohol of 1 ~ 6 carbon, and more preferably methyl alcohol, ethanol, Virahol, ethylene glycol or propylene glycol, most preferably be ethanol.The described preferred benzene of aromatic hydrocarbon containing 6 ~ 8 carbon, toluene or dimethylbenzene, more preferably toluene.Consumption preferably 5 ~ 20ml/g compound 1 of described organic solvent, more preferably 5 ~ 15ml/g compound 1.Described solvent participates in reaction again preferably through Non-aqueous processing.The condition of described Non-aqueous processing and step can be selected according to the condition of the Non-aqueous processing of this area routine and step.
There is no particular limitation for described alkali, those skilled in the art can be applicable to alkali of the present invention according to conventional in selecting response this area of the present invention, the alkalide of preferred organic amine, nitrogen heteroaromatic rings, basic metal, alcohol, hydrogenated alkali metal, alkali-metal amides, n-Butyl Lithium or lithium aluminum hydride.The preferred diethylamine of described organic amine, triethylamine or DIPEA.The preferred pyridine of described nitrogen heteroaromatic rings, imidazoles, 2,6-lutidine or 1,2,4-triazole.The preferred sodium of described basic metal.The alkalide particular methanol sodium of described alcohol, sodium ethylate or sodium tert-butoxide, more preferably sodium methylate.The preferred sodium hydride of described hydrogenated alkali metal.The described preferred sodium amide of alkali-metal amides.The mol ratio of described alkali and compound 1 preferably 0.1: 1 ~ 0.5: 1, more preferably 0.1: 1 ~ 0.3: 1.
The mol ratio of described compound 1 and compound 5 preferably 0.3: 1 ~ 1.5: 1, more preferably 0.5: 1 ~ 0.8: 1.
Described temperature of reaction preferably 40 DEG C ~ 120 DEG C, more preferably 80 DEG C ~ 100 DEG C.
The process of described reaction can be monitored by TLC or HPLC, as the terminal of reaction when generally disappearing using compound 1.
The intermediate 3 obtained by above-mentioned preparation method also can carry out purifying through last handling process.Described last handling process can be the last handling process of this area routine, preferably include the following step: reaction system is cooled to room temperature (25 DEG C ~ 30 DEG C), add water wash with diluted ethyl acetate, aqueous phase ethyl acetate is extracted once, merge organic phase and successively with the aqueous hydrochloric acid of 1N, saturated aqueous sodium carbonate, water and saturated sodium-chloride water solution wash to pH be 6 ~ 7, then anhydrous sodium sulfate drying is used, except desolventizing.
Described reacting middle catalyst is not a prerequisite, and those skilled in the art can select suitable catalyzer to optimize reaction further for the present invention; Also can select not add catalyzer.
Present invention also offers the preparation method of the full ketone I of a kind of halogenated pyrrole substituted indole, it comprises the following steps: 1. to obtain compound 3 by above-mentioned preparation method; 2. temperature of reaction is 25 DEG C ~ 120 DEG C, in organic solvent, and under the effect of alkali, the compound 3 and the 5-fluorine oxindoles (compound 4) that step are 1. obtained react, and obtain Compound I;
2. described step, preferably includes the following step: be dissolved in organic solvent by compound 3, adds alkali successively and compound 4 mixes, and react, obtain Compound I, temperature of reaction is 25 DEG C ~ 120 DEG C.
Step 2. in, there is no particular limitation for described organic solvent, those skilled in the art can be applicable to organic solvent of the present invention according to what commonly use in selecting response this area of the present invention, preferred DMF, N-Methyl pyrrolidone, ether, alcohol or the aromatic hydrocarbon containing 6 ~ 8 carbon.Preferred Isosorbide-5-Nitrae-the dioxane of described ether, tetrahydrofuran (THF), glycol dimethyl ether or trimethyl carbinol dme.Described alcohol particular methanol, ethanol, Virahol, ethylene glycol or propylene glycol, be more preferably Virahol.The described preferred benzene of aromatic hydrocarbon containing 6 ~ 8 carbon, toluene or dimethylbenzene.The consumption of described organic solvent is preferably 10 ~ 30ml/g compound 4, more preferably 10 ~ 20ml/g compound 4.
Step 2. in, there is no particular limitation for described alkali, and those skilled in the art can be applicable to alkali of the present invention, preferred organic amine or nitrogen heteroaromatic rings according to conventional in selecting response this area of the present invention.The preferred diethylamine of described organic amine, triethylamine or DIPEA, more preferably triethylamine.The preferred pyridine of described nitrogen heteroaromatic rings, imidazoles, 2,6-lutidine or 1,2,4-triazole.Step 2. in, described alkali and step 1. in the mol ratio preferably 0.1: 1 ~ 0.5: 1 of compound 1, more preferably 0.2: 1 ~ 0.3: 1.
Step 2. in, described compound 4 and step 1. in the mol ratio preferably 0.5: 1 ~ 1.5: 1 of compound 1, more preferably 0.8: 1 ~ 1.2: 1.
Step 2. in, described temperature of reaction preferably 50 DEG C ~ 90 DEG C, more preferably 70 DEG C ~ 85 DEG C.
Step 2. in, the process of described reaction can be monitored by TLC or HPLC, when generally disappearing using compound 3 as reaction terminal.
The full ketone I of the halogenated pyrrole substituted indole obtained by above-mentioned preparation method also can carry out purifying through last handling process.Described last handling process can be the last handling process of this area routine, preferably includes the following step: reaction system is cooled to room temperature (25 DEG C ~ 30 DEG C), suction filtration, with absolute ethanol washing filter cake.
Without prejudice to the field on the basis of common sense, above-mentioned each optimum condition, can arbitrary combination, obtains the preferred embodiments of the invention.
Agents useful for same of the present invention and raw material are all commercially.
Positive progressive effect of the present invention is: the present invention is by one-step synthesis intermediate N [2-(diethylin) ethyl] the chloro-5-carboxaldehyde radicals of-2-methyl-4--3-methylpyrrol carboxamides, shorten reactions steps, avoid operational difficulty in compound 2 aftertreatment; Simultaneously, optimize the reaction conditions of preparation I compound, the total recovery of reaction is 50 ~ 60%, comparatively the total recovery of 38% in the synthetic method reported of Chinese patent (CN101440086A) is significantly improved, in addition, owing to shortening synthesis step, thus cost is reduced, make operation simpler, be more suitable for suitability for industrialized production.
Embodiment
Mode below by embodiment further illustrates the present invention, but does not therefore limit the present invention among described scope of embodiments.The experimental technique of unreceipted actual conditions in the following example, conventionally and condition, or selects according to catalogue.
The preparation of embodiment 1 formula I
By the chloro-5-carboxaldehyde radicals of 2-methyl-4--3-minaline ethyl ester (3g, 14mmol), dehydrated alcohol 30ml, N, N-diethyl ethylenediamine (2.42g, 21mmol), sodium methylate (0.15g, 2.7mmol) mix, heat 80 DEG C of reactions 10 hours, cooling, reaction solution 300ml diluted ethyl acetate also adds 300ml water washing, aqueous phase 100ml ethyl acetate is extracted once, merge organic interdependent secondary 1NHCl (100ml), saturated sodium carbonate solution (100ml), water (200ml × 2) and saturated brine (200ml) washing are to pH=6-7, organic phase anhydrous sodium sulfate drying, pressure reducing and steaming solvent, dehydrated alcohol 30ml is added successively in residuum, triethylamine (0.42g, 4mmol) with 5-fluorine oxindoles (1.89g, 12mol) mix, heat 80 DEG C of reactions 4 hours, be cooled to room temperature, suction filtration, with appropriate absolute ethanol washing filter cake, obtain 3.38g formula I, yield is 58%, purity 98.10%.
Compound I
1hNMR (DMSO-d
6): δ 13.85 (s, 1H); 11.06 (s, 1H); 6.83-7.73 (m, 5H); 3.27 (m, 2H); 2.45-2.54 (m, 9H); 0.949 (t, 6H).
The preparation of embodiment 2 formula I
By the chloro-5-carboxaldehyde radicals of 2-methyl-4--3-minaline ethyl ester (3g, 14mmol), dry toluene 30ml, N, N-diethyl ethylenediamine (2.02g, 17mmol), NaH (0.167g, 6.9mmol) mix, room temperature reaction 9 hours, cooling, reaction solution 300ml diluted ethyl acetate also adds 300ml water washing, aqueous phase 100ml ethyl acetate is extracted once, merge organic interdependent secondary 1NHCl (100ml), saturated sodium carbonate solution (100ml), water (200ml × 2) and saturated brine (200ml) washing are to pH=6-7, organic phase anhydrous sodium sulfate drying, pressure reducing and steaming solvent, Virahol 30ml is added successively in residuum, N, N-diisopropyl ethylenediamine (0.9g, 6mmol) with 5-fluorine oxindoles (2.11g, 14mol) mix, heat 80 DEG C of reactions 4 hours, be cooled to room temperature, suction filtration, with appropriate absolute ethanol washing filter cake, obtain 3g formula I, yield is 50%, purity 98.51%.
Compound I
1hNMR (DMSO-d
6): δ 13.85 (s, 1H); 11.06 (s, 1H); 6.83-7.73 (m, 5H); 3.27 (m, 2H); 2.45-2.54 (m, 9H); 0.949 (t, 6H).
The preparation of embodiment 3 formula I
By the chloro-5-carboxaldehyde radicals of 2-methyl-4--3-minaline ethyl ester (3g, 14mmol), anhydrous isopropyl alcohol 30ml, N, N-diethyl ethylenediamine (1.62g, 14mmol), triethylamine (0.28g, 2.8mmol) mix, heat 40 DEG C of reactions 10 hours, cooling, reaction solution 300ml diluted ethyl acetate also adds 300ml water washing, aqueous phase 100ml ethyl acetate is extracted once, merge organic interdependent secondary 1NHCl (100ml), saturated sodium carbonate solution (100ml), water (200ml × 2) and saturated brine (200ml) washing are to pH=6-7, organic phase anhydrous sodium sulfate drying, pressure reducing and steaming solvent, toluene 30ml is added successively in residuum, 2, 6-lutidine (0.3g, 2.8mmol) with 5-fluorine oxindoles (2.75g, 18.2mol) mixing, heat 80 DEG C of reactions 3 hours, be cooled to room temperature, suction filtration, with appropriate absolute ethanol washing filter cake, obtain 3.5g formula I, yield is 60%, purity 98.23%.
Compound I
1hNMR (DMSO-d
6): δ 13.85 (s, 1H); 11.06 (s, 1H); 6.83-7.73 (m, 5H); 3.27 (m, 2H); 2.45-2.54 (m, 9H); 0.949 (t, 6H).
The preparation of embodiment 4 formula I
By the chloro-5-carboxaldehyde radicals of 2-methyl-4--3-minaline ethyl ester (3g, 14mmol), anhydrous tetrahydro furan 30ml, N, N-diethyl ethylenediamine (3.25g, 28mmol), 2, 6-lutidine (0.45g, 4.2mmol) mix, heat 40 DEG C of reactions 10 hours, cooling, reaction solution 300ml diluted ethyl acetate also adds 300ml water washing, aqueous phase 100ml ethyl acetate is extracted once, merge organic interdependent secondary 1NHCl (100ml), saturated sodium carbonate solution (100ml), water (200ml × 2) and saturated brine (200ml) washing are to pH=6-7, organic phase anhydrous sodium sulfate drying, pressure reducing and steaming solvent, tetrahydrofuran (THF) 30ml is added successively in residuum, triethylamine (0.56g, 5.6mmol) with 5-fluorine oxindoles (2.54g, 16.8mol) mixing, heat 80 DEG C of reactions 3 hours, be cooled to room temperature, suction filtration, with appropriate absolute ethanol washing filter cake, obtain 4g formula I, yield is 68%, purity 98.03%.
Claims (7)
1. a preparation method for the dihydroindole ketone intermediate 3 of halogenated pyrrole replacement, it comprises the following steps: that temperature of reaction is 0 DEG C ~ 150 DEG C, in organic solvent, under the effect of alkali, compound 1 and compound 5 is reacted, obtains intermediate 3; The mol ratio of described alkali and compound 1 is 0.1:1 ~ 0.5:1; Described organic solvent is DMF, N-Methyl pyrrolidone, Isosorbide-5-Nitrae-dioxane, tetrahydrofuran (THF), glycol dimethyl ether, trimethyl carbinol dme, benzene,toluene,xylene, methyl alcohol, ethanol, Virahol, ethylene glycol or propylene glycol; Described alkali is diethylamine, triethylamine, DIPEA, pyridine, imidazoles, 2,6-lutidine or 1,2,4-triazole, sodium methylate, sodium ethylate or sodium tert-butoxide;
2. the preparation method of the dihydroindole ketone intermediate 3 of halogenated pyrrole replacement as claimed in claim 1, is characterized in that: the mol ratio of described alkali and compound 1 is 0.1:1 ~ 0.3:1.
3. the preparation method of the dihydroindole ketone intermediate 3 of halogenated pyrrole replacement as claimed in claim 1, is characterized in that: described compound 1 is 0.3:1 ~ 1.5:1 with the mol ratio of compound 5; Described temperature of reaction is 40 DEG C ~ 120 DEG C.
4. the preparation method of the dihydroindole ketone intermediate 3 of halogenated pyrrole replacement as claimed in claim 3, is characterized in that: described compound 1 is 0.5:1 ~ 0.8:1 with the mol ratio of compound 5; Described temperature of reaction is 80 DEG C ~ 100 DEG C.
5. a preparation method of the full ketone I of halogenated pyrrole substituted indole, it comprises the following steps: 1. to obtain compound 3 by the preparation method described in any one of Claims 1 to 4; 2. temperature of reaction is 25 DEG C ~ 120 DEG C, in organic solvent, and under the effect of alkali, the compound 3 and the compound 4 that step are 1. obtained react, and obtain Compound I;
Step 2. in, described organic solvent is N, dinethylformamide, N-Methyl pyrrolidone, Isosorbide-5-Nitrae-dioxane, tetrahydrofuran (THF), glycol dimethyl ether, trimethyl carbinol dme, methyl alcohol, ethanol, Virahol, ethylene glycol, propylene glycol, benzene, toluene or dimethylbenzene; Step 2. in, described alkali is diethylamine, triethylamine, DIPEA, pyridine, imidazoles, 2,6-lutidine or 1,2,4-triazole.
6. the preparation method of the full ketone I of halogenated pyrrole substituted indole as claimed in claim 5, it is characterized in that: 2. described step comprises the following steps: compound 3 to be dissolved in organic solvent, add alkali successively and compound 4 mixes, react, obtain Compound I, temperature of reaction is 25 DEG C ~ 120 DEG C;
Step 2. in, described alkali and step 1. in the mol ratio of compound 1 be 0.1:1 ~ 0.5:1;
Step 2. in, described compound 4 and step 1. in the mol ratio of compound 1 be 0.5:1 ~ 1.5:1; Step 2. in, described temperature of reaction is 50 DEG C ~ 90 DEG C.
7. the preparation method of the full ketone I of halogenated pyrrole substituted indole as claimed in claim 6, is characterized in that: step 2. in, the mol ratio of described alkali and step 1. middle compound 1 is 0.2:1 ~ 0.3:1; Step 2. in, described compound 4 and step 1. in the mol ratio of compound 1 be 0.8:1 ~ 1.2:1; Step 2. in, described temperature of reaction is 70 DEG C ~ 85 DEG C.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210036869.2A CN103254110B (en) | 2012-02-17 | 2012-02-17 | The full ketone of halogenated pyrrole substituted indole, its intermediate and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210036869.2A CN103254110B (en) | 2012-02-17 | 2012-02-17 | The full ketone of halogenated pyrrole substituted indole, its intermediate and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103254110A CN103254110A (en) | 2013-08-21 |
| CN103254110B true CN103254110B (en) | 2015-12-16 |
Family
ID=48958382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210036869.2A Expired - Fee Related CN103254110B (en) | 2012-02-17 | 2012-02-17 | The full ketone of halogenated pyrrole substituted indole, its intermediate and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103254110B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002096361A2 (en) * | 2001-05-30 | 2002-12-05 | Sugen, Inc. | 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors |
| CN101255154A (en) * | 2008-02-18 | 2008-09-03 | 靳广毅 | Substituted 2-indoline ketone derivatives as well as preparation method and uses thereof |
| CN101333215A (en) * | 2008-07-29 | 2008-12-31 | 南京工业大学 | Synthesis method of sunitinib alkali |
| CN101440086A (en) * | 2007-11-20 | 2009-05-27 | 上海医药工业研究院 | Halogenated pyrrole substituted indolinones, and intermediate, preparation and use thereof |
| CN101885698A (en) * | 2009-05-15 | 2010-11-17 | 浙江海正药业股份有限公司 | Pyrrolyl acrylamide compound and application thereof to synthesis of sunitinib |
| CN102030741A (en) * | 2009-09-28 | 2011-04-27 | 上海朗莱医药科技中心 | Halogenated pyrrole-substituted 2-indolinone salt and preparation method and application thereof |
-
2012
- 2012-02-17 CN CN201210036869.2A patent/CN103254110B/en not_active Expired - Fee Related
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002096361A2 (en) * | 2001-05-30 | 2002-12-05 | Sugen, Inc. | 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors |
| CN101440086A (en) * | 2007-11-20 | 2009-05-27 | 上海医药工业研究院 | Halogenated pyrrole substituted indolinones, and intermediate, preparation and use thereof |
| CN101255154A (en) * | 2008-02-18 | 2008-09-03 | 靳广毅 | Substituted 2-indoline ketone derivatives as well as preparation method and uses thereof |
| CN101333215A (en) * | 2008-07-29 | 2008-12-31 | 南京工业大学 | Synthesis method of sunitinib alkali |
| CN101885698A (en) * | 2009-05-15 | 2010-11-17 | 浙江海正药业股份有限公司 | Pyrrolyl acrylamide compound and application thereof to synthesis of sunitinib |
| CN102030741A (en) * | 2009-09-28 | 2011-04-27 | 上海朗莱医药科技中心 | Halogenated pyrrole-substituted 2-indolinone salt and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103254110A (en) | 2013-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fang et al. | Novel robust benzimidazolylidene palladium complexes: synthesis, structure, and catalytic applications in amination of chloroarenes | |
| CN107879989B (en) | 3,4, 5-substituted benzodiazepine 2-one drug molecule with biological activity and preparation method thereof | |
| CN106831716A (en) | A kind of crystal form of ALK inhibitor | |
| CN110067006B (en) | Method for electrochemically synthesizing sulfonyl hydrazino indole compound and application | |
| CA3126738C (en) | Preparation method for morpholinquinazoline compound and midbody thereof | |
| JP6454669B2 (en) | Process for producing 1,4-benzoxazine compounds | |
| CN107216313A (en) | A kind of antineoplastic AZD9291 preparation method | |
| CN106632033A (en) | Preparation method of lenvatinib | |
| CN110054584B (en) | 1-aryl-3- {4- [ (pyridin-2-ylmethyl) thio ] phenyl } urea compound and application thereof | |
| Zhu et al. | Copper (I)-promoted trifluoromethylation of indole derivates with concomitant C–C bond formation to access fused tricyclic indoles | |
| CN103254110B (en) | The full ketone of halogenated pyrrole substituted indole, its intermediate and preparation method thereof | |
| CN103880822A (en) | 2,4,6-trisubstituted pyrimidine compounds containing 1,2,3-triazole, preparation method and application thereof | |
| CN105924431A (en) | Synthesis process for compound crizotinib | |
| CN110028444B (en) | 1-aryl-3- [4- (pyridine-2-yl methoxy) phenyl ] urea compound and application thereof | |
| CN102863371A (en) | Fluoro dihydropyrrole or fluoro pyrrole | |
| CN105541808A (en) | Metronidazole-isatin type compound as well as preparation method and application thereof | |
| CN113603651B (en) | Method for preparing 3-sulfur substituted quinoxalinone derivatives by catalysis | |
| CN106957237B (en) | A method of synthesis bromfenac sodium | |
| CN112174901B (en) | Synthesis method and anticancer activity of 1, 3-benzodiazepine compound | |
| CN108623511A (en) | A kind of indole amides class compound can be used for treating cancer | |
| CN111004164B (en) | Preparation method of polysubstituted 2-aryl indole derivative | |
| CN105669516B (en) | A kind of preparation method of 3,3 '-bis-benzazolyl compounds | |
| CN104672180B (en) | Chiral preparation method of [(1S)-3-methyl-1-[[(2R)-2-methylepoxyethyl]carbonyl]butyl]tert-butyl carbamate | |
| KR20180096572A (en) | Manufacturing method of copari | |
| CN111499622A (en) | Preparation method of medicine for treating bile duct cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151216 Termination date: 20210217 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |